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Abstract 
Primary  gastric  chorioadenocarcinoma
(PGC) is an exceedingly rare neoplasm which
is often misdiagnosed as gastric adenocarcino-
ma at presentation. A markedly elevated serum
beta  human  chorionic  gonadotrophin  (Beta
HCG) level is a characteristic feature of this
tumor. A 44 year old white male presented with
generalized abdominal pain and fullness, tarry
black stools and weight loss of 3 months dura-
tion. Medical work-up including imaging with
CT scans revealed the presence of a gastric
mass  and  multiple  liver  metastases.  Tumor
markers  were  significant  for  a  beta  human
chorionic  gonadotrophin  (Beta  HCG)  of
23717.5  MIU/ML.  Scrotal  ultrasound  did  not
show the presence of a testicular mass. Upper
GI endoscopy with biopsy was positive for a
poorly  differentiated  adenocarcinoma  with
Beta HCG staining on immunohistochemistry.
The  patient  was  diagnosed  with  metastatic
PGC. He received four cycles of chemotherapy
with Bleomycin, Etoposide and Cisplatinum. At
the end of the fourth cycle, Beta HCG was 23
MIU/ML.  CT  scan  for  restaging,  however
showed an increase in the size of the metasta-
tic lesions. The patient subsequently became
profoundly  pancytopenic,  developed  dissemi-
nated  intravascular  coagulation  (DIC)  and
expired 12 months after initial presentation.
PGC  genetically  and  morphologically  repre-
sents an adenocarcinoma and a choriocarcino-
ma.  The  significance  of  an  elevated  serum
Beta HCG is controversial and it may have a
role in evaluating response to treatment and
tumor recurrence. Curative resection, appro-
priate  chemotherapy  and  the  absence  of
metastatic lesions is associated with improved
survival.  Hence,  a  high  index  of  suspicion
must  be  maintained  to  diagnose  this  tumor
correctly  at  presentation  and  tailor  therapy
accordingly.
Introduction
Primary  gastric  chorioadenocarcinoma
(PGC) is an exceedingly rare neoplasm with
approximately 30 PGC cases reported to date in
the English-language medical literature.1 PGC
accounts for less than 1% of all gastric malig-
nancies.2 As  the  name  suggests,  the  tumor
consists  of  gastric  adenocarcinoma  cells
admixed with cytotrophoblast and syncytiotro-
phoblast cells that constitute the choriocarci-
nomatous component. The first clue to diagno-
sis is often a markedly elevated serum beta
human chorionic gonadotrophin (Beta HCG)
level.3-5 We describe an interesting case of PGC
that was treated at our institution, with an ini-
tial  dramatic  response  to  chemotherapy  and
gradual progression thereafter. 
History and presentation 
A 44 year old white male with no significant
past medical history presented with general-
ized abdominal pain and tarry black stools of 3
months  duration.  He  also  complained  of
increased abdominal girth, abdominal fullness,
night  sweats,  weight  loss  and  fever  of  2
months duration. Physical exam was signifi-
cant for a distended abdomen which was ten-
der to palpation in the right upper quadrant.
Computerized tomography (CT) of the thorax
(Figure 1), abdomen and pelvis revealed medi-
astinal lymphadenopathy, bilateral pulmonary
nodules, and an abnormally increased thick-
ness of the wall of the body of the stomach. An
8.0¥5.7 cm soft tissue mass adjacent to the
lesser  curvature  of  the  stomach  which  was
extending caudally to the level of the pancreas
(Figure 2).  
There were a few slightly enlarged lymph
nodes adjacent to the pancreatic head and in
the porta hepatis, multiple mass lesions in the
right and the left lobe of the liver and moderate
ascites. Tumor markers were significant for a
markedly  elevated  Beta  HCG  of  23717.5
MIU/ML and elevated alpha fetoprotein (AFP)
of  21.07  NG/ML.  Scrotal  ultrasound  did  not
reveal the presence of a testicular mass. The
patient underwent an upper GI endoscopy with
biopsy which revealed a malignant appearing
ulcerated mass involving the whole gastric car-
dia. Biopsy of the mass was consistent with a
poorly differentiated carcinoma with features
of  a  chorioadenocarcinoma.  Immunohisto  -
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Figure 1. Computerezed tomography scan
of  the  abdomen  with  contrast.  Increased
thickness of the wall of the body of the
stomach and multiple metastatic lesions in
the right and left lobe of the liver.
Figure 2. Computerezed tomography scan
of the abdomen with contrast. An 8.0 X
5.7 cm soft tissue mass adjacent to the less-
er curvature of the stomach extending cau-
dally to the level of the pancreas. Multiple
metastatic lesions in the right and left lobe
of the liver.[Rare Tumors 2011; 3:e19] [page 57]
chemical  staining  was  strongly  positive  for
Beta HCG in a large component of the biopsied
mass (Figure 3, 4). CT guided FNA and core
biopsy of the liver showed pleomorphic cells
with a high mitotic rate and large irregular
nuclei  consistent  with  choriocarcinoma
(Figure 5). In the absence of a primary testic-
ular mass, the patient was diagnosed with a
primary  gastric  chorioadenocarcinoma  with
liver, lung and mediastinal metastasis.
As the patient had extensive metastatic dis-
ease on presentation, a surgical procedure to
decrease  tumor  burden  would  have  involved
high  morbidity.  Hence,  chemotherapy  with
bleomycin, etoposide and cisplatin (BEP) was
started,  to  decrease  the  tumor  burden.
Chemotherapy was interrupted, initially due to
tumor lysis syndrome and acute tubular necro-
sis  causing  acute  renal  failure  secondary  to
cisplatin  which  subsequently  resolved,  and
then  due  to  recurrent  Clostridium  difficile
infections. 
At the end of 4 cycles of chemotherapy with
BEP,  the  tumor  markers  showed  dramatic
improvement,  with  Beta  HCG  down  to  23
MIU/ML from 23,717 MIU/ML at initial presen-
tation. A repeat CT scan for restaging showed
decrease in size of the gastric mass and liver
lesions but increased right sided mediastinal
lymphadenopathy. Despite the initial dramatic
response of the tumor markers to chemothera-
py,  the  metastatic  lesions  in  the  liver  and
ascites  continues  to  progress.  The  patient
eventually had bone marrow involvement with
tumor  and  became  profoundly  pancytopenic,
necessitating  multiple  transfusions.  He  ulti-
mately  developed  disseminated  intravascular
coagulation (DIC) and passed away 12 months
from initial presentation and diagnosis.
Discussion
The genesis of PGC, a rare and interesting
tumor,  is  still  a  subject  of  controversy.
Scientific opinion appears to support the ded-
ifferentiation theory first proposed by Pick in
1926.1 Liu et al.6 reported the first interphase
cytogenetics study of PGC, the results of which
support the theory that gastric chorioadeno-
carcinoma  arises  from  alternate  differentia-
tion pathways of adenocarcinoma. Except for
the gain of chromosome 12, which is known to
be uncommon in gastric adenocarcinoma but
frequently  associated  with  choriocarcinoma,
the  remaining  genomic  imbalances(gains  of
function mutations in 2q, 7pq, 8pq, 13q, 17q,
18q, 20pq and deletions in 17p)7 were among
the  most  common  comparative  genomic
hybridization findings reported in gastric ade-
nocarcinoma. Several other studies have indi-
cated  that  the  pathogenesis  of  PGC  can  be
explained  as  the  dedifferentiation  of  malig-
nant adenocarcinoma tissue to the level of the
embryonal ectoderm, retaining the ability to
form trophoblasts.4 Hence due to the coexis-
tence  of  adenocarcinoma  and  choriocarcino-
ma, PGC is often misdiagnosed as an adeno-
carcinoma at presentation. Only 8% of the PGC
cases in a pooled analysis of 53 cases were cor-
rectly diagnosed as choriocarcinoma by biop-
sy.1 On gross appearance, gastric choriocarci-
nomas are exophytic. They are generally more
beefy red and hemorrhagic than typical gastric
adenocarcinomas, given their striking vascu-
larity.3 Histologically, there is a combination of
malignant  cytotrophoblast  and  syncytiotro-
phoblast, generally admixed with areas of typi-
cal glandular differentiation.3
The syncytiotrophoblast cells stain positive
for Beta HCG on immunohistochemistry.8 Most
cases of PGC described in the literature have
been  accompanied  by  elevated  Beta  HCG  at
presentation.3-5 This  is  responsible  for  the
morning  sickness  like  symptoms  in  women
and gynecomastia in men presenting with this
tumor.3 The presence of the beta-HCG-positive
cells in the gastric carcinomas suggested no
appreciable  prognostic  significance,  even
quantitatively.8However, the significance of an
elevated serum Beta-HCG in gastric choriocar-
cinoma is still controversial. While some stud-
ies suggest that it is associated with a short-
ened  survival  and  poorer  prognosis,  others
suggest that it has no prognostic significance.5
Nonetheless, monitoring serial levels of Beta
HCG  post-operatively  or  post-chemotherapy
may  be  a  useful  marker  for  evaluating
response to treatment and tumor recurrence. 
The major entity in the differential diagno-
sis of PGC is metastatic trophoblastic tumor
from other sites, particularly gonadal or gesta-
tional  primaries  in  women  of  reproductive
age.3 Although the number of well-documented
cases of gastric choriocarcinomas reported to
date  is  small,  it  appears  that  these  tumors
behave  more  like  gestational  or  germ  cell
choriocarcinomas  with  rapid  and  extensive
hematogenous  dissemination  as  opposed  to
the preferred lymphatic spread of adenocarci-
nomas. Metastatic disease frequently contains
pure  choriocarcinoma,  although  mixed
chorioadenocarcinoma  metastases  have  also
been seen.5
This may explain the initial response of the
metastatic  lesions  to  platinum  based
chemotherapy and the initial large decrease in
Beta  HCG  in  our  patient  whose  metastatic
lesions on liver biopsy had pathology consis-
tent with choriocarcinoma.
Gastrectomy with lymph node dissection fol-
lowed by postoperative chemotherapy is the 
treatment of choice in patients with a limit-
ed tumor burden.3 This treatment guideline is
more by consensus than evidence-based prac-
tice. Kobayashi et al.1 reported that the pres-
ence of residual tumor and synchronous liver
metastasis and the absence of chemotherapy
were  significantly  associated  with  an
increased  hazard  rate  (HR)  of  short  overall
survival (OS). They suggest that a palliative
gastrectomy  should  never  be  performed  in
patients with synchronous liver metastasis, as
it is likely to contribute to early post-procedure
mortality. One may hence argue that it is bet-
ter  to  first  treat  patients  with  synchronous
metastasis at presentation with chemotherapy
and monitor them with serial tumor marker
levels and serial imaging for response prior to
Case Report
Figure  3.  Immunohistochemical  stain.
Gastric  biopsy  specimen  with  intestinal-
type adenocarcinoma composed of colum-
nar gland forming cells interspersed with
cytotrophoblast  and  syncytiotrophoblast
cells  staining  positve  for  Beta  HCG  on
IHC (Immunohistochemistry).
Figure  4.  Immunohistochemical  stain.
Gastric biopsy specimen from the patient
with  Beta  HCG  staining  (brown)  on
Immunohistochemistry.
Figure 5. Hematoxylin & Eosin stain. The
tumor appears to be pleomorphic with a
high mitotic rate. There are several large
cells with large irregular nuclei.[page 58] [Rare Tumors 2011; 3:e19]
considering an operative procedure. Noguchi
et al.9have reported a good treatment response
with the combination therapy of 5-flurouracil
and cisplatin.
Conclusion
PGC is a rare malignancy which has been
identified and reported from time to time from
different parts of the world, most notably Japan
and the United States. A high index of suspi-
cion  must  be  entertained  to  diagnose  this
tumor,  as  it  is  commonly  misdiagnosed  on
biopsy. Elevate Beta HCG is a clue obtained at
presentation.  Most  of  the  tumors  are  at  an
advanced  stage  at  presentation  and  have  a
poor prognosis. PGC is not as chemotherapy
sensitive  as  pure  choriocarcinomas.  Despite
having a pooled analysis of 53 cases reported,
there  are  no  clear  guidelines  yet  about  the
appropriate treatment protocol for this tumor.
A larger sample size and more data analysis
will be required to address the issue of finding
an appropriate chemotherapy regimen.
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